Intraoperative margin assessment during BCS using Perimeter B-Series OCT with ImgAssist AI 2.0 enabled surgeons to more effectively address residual cancer at the surgical margin as compared to current standard methods Primary endpoint met with statistically significant reduction in...Read more
PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy expansion trials to begin dosing 1Q25 Overall, 26% ORR across all six...Read more
LOS ANGELES / Nov 20, 2024 / Business Wire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA™-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in combination with endocrine therapy for the...Read more
New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology,...Read more
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR)...Read more
Sangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 RICHMOND, Calif. / Nov 19, 2024 / Business Wire / Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has cleared...Read more
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 23.68 3.25 | $753.41 |
| UnitedHealth | 23.50 4.07 | $600.50 |
| argenx | 17.28 3.01 | $591.82 |
| Humana | 16.19 5.83 | $293.97 |
| Alnylam Pharmaceuticals | 14.52 6.20 | $248.79 |
| Waters | 13.06 3.79 | $357.77 |
| Semler Scientific | 12.69 27.38 | $59.03 |
| Molina Healthcare | 12.14 4.30 | $294.64 |
| Medpace | 11.13 3.53 | $326.09 |
| Repligen | 10.41 8.10 | $138.90 |
| Finch Therapeutics | 9.65 536.11 | $11.45 |
| Inspire Medical Systems | 8.72 4.95 | $184.77 |
| Amgen | 8.13 2.90 | $288.08 |
| ICON | 8.07 4.13 | $203.67 |
| West Pharmaceutical | 7.56 2.49 | $311.66 |
| Forte Biosciences | 7.50 126.48 | $13.43 |
| Lantheus | 7.02 8.84 | $86.45 |
| BeiGene | 6.24 3.32 | $194.01 |
| Company | Volume | Last Trade |
|---|---|---|
| Tonix Pharmaceuticals | 654,513,644 | $0.19 |
| Quantum-Si | 278,845,174 | $1.38 |
| Pfizer | 44,158,947 | $24.92 |
| Vyome | 36,361,564 | $0.22 |
| Forte Biosciences | 29,378,859 | $13.43 |
| Eyenovia | 27,950,523 | $0.09 |
| Lineage Cell Therapeutics | 27,898,971 | $0.64 |
| Walgreens Boots Alliance | 24,873,335 | $8.21 |
| Exicure | 22,755,368 | $11.04 |
| Senseonics | 20,535,852 | $0.32 |
| Syros Pharmaceuticals | 16,804,532 | $0.28 |
| The Oncology Institute | 14,714,212 | $0.13 |
| Recursion | 14,375,750 | $6.04 |
| Aptevo Therapeutics | 12,599,179 | $0.29 |
| Seres Therapeutics | 12,189,542 | $0.83 |
| CVS Health | 11,060,119 | $56.83 |
| Bristol-Myers Squibb | 10,049,951 | $57.88 |
| Apollomics | 9,889,155 | $0.14 |
| Geron | 9,404,214 | $3.99 |
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
